Literature DB >> 26440603

Drug-Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose Metabolism.

U Anyanwagu1, I Idris1, R Donnelly1.   

Abstract

Abnormalities of glucose metabolism and glucose tolerance, either because of a reduction in tissue sensitivity to insulin (e.g., in liver, skeletal muscle, and adipose tissues) and/or a reduction in pancreatic insulin secretion, are associated with a number of unwanted health outcomes. Even small increases in circulating glucose levels (often described as dysglycemia or prediabetes) may confer an increased risk of cardiovascular (CV) disease and progression to overt type 2 diabetes. A number of drug therapies, many of them used long term in chronic disease management, have adverse effects on glucose metabolism, diabetes risk, and glycemic control among patients with preexisting diabetes. In this study, we review the evidence, underlying mechanisms, and the clinical significance of drug-related adverse effects on glucose metabolism.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26440603     DOI: 10.1002/cpt.274

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.

Authors:  Yan Zheng; Sylvia H Ley; Frank B Hu
Journal:  Nat Rev Endocrinol       Date:  2017-12-08       Impact factor: 43.330

2.  Prevalence of Self-Reported Diabetes by Sexual Orientation: Results from the 2014 Behavioral Risk Factor Surveillance System.

Authors:  Lauren B Beach; Tom A Elasy; Gilbert Gonzales
Journal:  LGBT Health       Date:  2018-01-29       Impact factor: 4.151

3.  Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.

Authors:  De-Juan Li; Qin Yue; Lu Liu; Ke-Ke Che; Xue-Mei Liu; Chang-Hua Hu
Journal:  Acta Pharmacol Sin       Date:  2021-05-11       Impact factor: 7.169

4.  Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study.

Authors:  Uchenna Anyanwagu; Jil Mamza; Richard Donnelly; Iskandar Idris
Journal:  Cardiovasc Diabetol       Date:  2017-08-22       Impact factor: 9.951

5.  Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea.

Authors:  Jinkwon Kim; Hye Sun Lee; Kyung-Yul Lee
Journal:  Cardiovasc Diabetol       Date:  2018-12-05       Impact factor: 9.951

6.  Drug-induced diabetes type 2: In silico study involving class B GPCRs.

Authors:  Dorota Latek; Ewelina Rutkowska; Szymon Niewieczerzal; Judyta Cielecka-Piontek
Journal:  PLoS One       Date:  2019-01-16       Impact factor: 3.240

7.  Time-varying and dose-dependent effect of long-term statin use on risk of type 2 diabetes: a retrospective cohort study.

Authors:  Eonji Na; Sunyoung Cho; Dae Jung Kim; Junjeong Choi; Euna Han
Journal:  Cardiovasc Diabetol       Date:  2020-05-16       Impact factor: 9.951

Review 8.  Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy.

Authors:  Mariël F van Stee; Albert A de Graaf; Albert K Groen
Journal:  Cardiovasc Diabetol       Date:  2018-06-30       Impact factor: 9.951

9.  Potential off-target effects of beta-blockers on gut hormone receptors: In silico study including GUT-DOCK-A web service for small-molecule docking.

Authors:  Pawel Pasznik; Ewelina Rutkowska; Szymon Niewieczerzal; Judyta Cielecka-Piontek; Dorota Latek
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.